Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary raynaud's phenomenon: A double-blind, randomized, cross-over study

Rheumatology (United Kingdom)

Volumn 53, Issue 4, 2014, Pages 658-664

  Lee, Eun Young ^a,b   Park, Jin Kyun ^a   Lee, Whal ^b   Kim, Yeo Koon ^b   Park, Claire Su Yeon ^a,c   Giles, Jon T ^d   Park, Jun Won ^a,b   Shin, Kichul ^a   Lee, Jeong Seok ^a,b   Song, Yeong Wook ^a,b   Lee, Eun Bong ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University College of Nursing ^*  (South Korea)

^d Columbia University ^*  (United States)

Author keywords

Amlodipine; Digital blood flow; Raynaud's phenomenon; Udenafil; Vasodilator

Indexed keywords

AMLODIPINE; UDENAFIL;

ADULT; ARTERY BLOOD FLOW; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGITAL ARTERY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FACE EDEMA; FEMALE; FINGER ULCER; FLUSHING; GENERALIZED EDEMA; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; TEMPERATURE; UNSPECIFIED SIDE EFFECT;

AMLODIPINE; DIGITAL BLOOD FLOW; RAYNAUD'S PHENOMENON; UDENAFIL; VASODILATOR;

ADULT; AMLODIPINE; CONNECTIVE TISSUE DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PYRIMIDINES; RAYNAUD DISEASE; SULFONAMIDES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84897853372     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket417     Document Type: Article

References (22)

1. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
2. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology 2005;44:145-50.
3. Thompson AE, Shea B, Welch V et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
4. Fries R, Shariat K, von Wilmowsky H et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
5. Caglayan E, Huntgeburth M, Karasch T et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-3.
6. De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs 2009;18:23-9.
7. Brueckner CS, Becker MO, Kroencke T et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
8. Ding H, Du W, Wang H et al. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology 2012;80:134-9.
9. Park HJ, Park JK, Park K et al. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med 2010;7:2209-16.
10. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
11. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
12. Kasukawa R, Tojo T, Miyawaki S et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Excerpta Medica 1987;41-7.
13. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
14. Anderson ME, Moore TL, Lunt M et al. The distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology 2007;46:533-8.
15. Chikui T, Izumi M, Eguchi K et al. Doppler spectral waveform analysis of arteries of the hand in patients with Raynaud's phenomenon as compared with healthy subjects. AJR Am J Roentgenol 1999;172:1605-9.
16. Rosato E, Gigante A, Barbano B et al. In systemic sclerosis macrovascular damage of hands digital arteries correlates with microvascular damage. Microvasc Res 2011;82:410-5.
17. Keberle M, Tony HP, Jahns R et al. Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using colour doppler ultrasound. Rheumatology 2000;39:1206-13.
18. Herrick AL, van den Hoogen F, Gabrielli A et al. Modifiedrelease sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
19. Schiopu E, Hsu VM, Impens AJ et al. Randomized placebo- controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
20. Kim BH, Lim HS, Chung JY et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008;65:848-54.
21. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 2007;292:H3057-64.
22. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988;28:990-4.